NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE

NCT01546909

CompletedPhase 4

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions: Diphtheria, Tetanus, Poliomyelitis

Interventions: Diphtheria, tetanus, polio and pertussis vaccination

Countries: France

PRIMARY OBJECTIVES * To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 * To describe one month after a booster dose of TETRAVAC-ACELLULAIRE the immune responses against diphtheria, tetanus, and poliovirus types 1, 2 and 3 SECONDARY OBJECTIVES * To describe other parameters of the antibody persistence against diphtheria, tetanus and poliomyelitis antigens * To describe other parameters of the immune responses to diphtheria, tetanus and poliomyelitis antigens one month after a booster dose of TETRAVAC-ACELLULAIRE * To describe the safety profile of a booster dose of TETRAVAC-ACELLULAIRE

Eligibility overview

Sex: ALL

Age: 11 Years to 13 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Healthy child 11 to 13 years of age previously vaccinated in Study F05-TdI-301

Exclusion Criteria:

* Immunization against diphtheria, tetanus, pertussis and/or poliomyelitis beyond Study F05-TdI-301
* Previous clinical or bacteriological diagnosis of diphtheria, tetanus, pertussis or poliomyelitis
* Known or suspected immune dysfunction
* Receipt of medications / vaccination that may interfere with study assessments
* Known true hypersensitivity to any of the vaccine components or to a vaccine containing the same substances
* Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition
* Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
* Any medical condition that might interfere with the evaluation of the study objectives
* Febrile illness
Locations (45)
  • Angers, France
  • Arras, France
  • Asnières, France
  • Bersée, France
  • Besançon, France
  • Besançon, France
  • Blois, France
  • Blois, France
  • Boulogne-Billancourt, France
  • Brest, France
  • Caen, France
  • Caen, France
  • Champdeniers, France
  • Châlons-en-Champagne, France
  • Chigny-les-Roses, France
  • Cholet, France
  • Clamart, France
  • Collombey Les Belles, France
  • Collombey Les Belles, France
  • Dax, France
  • Draguignan, France
  • Essey-lès-Nancy, France
  • Essey-lès-Nancy, France
  • Essey-lès-Nancy, France
  • Floirac, France
  • Frouard, France
  • Haguenau, France
  • Illkirch-Graffenstaden, France
  • Le Havre, France
  • Le Havre, France
  • + 15 more on CT.gov